Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cicadea Biotech LLC is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is being reviewed by 1 distinct examiner, OYEYEMI, OLAYINKA A, who is also the busiest examiner with 1 busiest examiner pending action. Because the total number of pending office actions is 1, OYEYEMI, OLAYINKA A is responsible for the company's entire active prosecution footprint at this time.
The portfolio's activity is further localized within 1 distinct art unit. This concentration suggests that the company's current patent efforts are focused on a specific technical niche within the Biotechnology & Pharmaceuticals sector. With only 1 pending office action and 1 distinct art unit involved, the administrative and legal complexity of the portfolio is currently minimal, as there are no competing examiner perspectives or art unit policies to reconcile.
For the practitioner, this data indicates a highly centralized prosecution environment. The success of the current portfolio depends on the outcome of the 1 pending office action assigned to OYEYEMI, OLAYINKA A. Practitioners should focus on the specific examination history and preferences of this 1 distinct examiner. Since there is only 1 distinct art unit, the strategy can be tailored specifically to the standards of that group without the need for a broader, multi-unit approach.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OYEYEMI, OLAYINKA A | 1 | 60.4% | +46.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18449442 | KIDNEY CANCER SCREENING METHODS | OYEYEMI, OLAYINKA A | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18449442 | KIDNEY CANCER SCREENING METHODS | OYEYEMI, OLAYINKA A | 1681 | §103§112DP | Non-Final OA | — | Pending | Aug 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial